גאלאפולד 123 מ"ג - Galafold 123 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | A16AX Various alimentary tract and metabolism products | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||||||||||
| צ×רת ××ª× | פ××× - PER OS | |||||||||||||
| צ×רת ××× ×× | קפס××× ×§×©×××, CAPSULE, HARD ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||||||||||
| ×ת×××× | Galafold is indicated for long-term treatment of adults and adolescents aged 12 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation. | |||||||||||||
| ||||||||||||||
| ×ת××ת ××× ×× | Posology and method of administration | |||||||||||||
| ×ת××××ת × ×× | Contraindications | |||||||||||||
| ת×פע×ת ××××× | Undesirable effects | |||||||||||||
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction | |||||||||||||
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation | |||||||||||||
| פר×ק×××× ×××§× | Pharmacodynamic Properties | |||||||||||||
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties | |||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | |||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ××××פ××× 123 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | AMICUS THERAPEUTICS UK LTD, UK |
| ×©× ××¢× ×ר×ש×× | TRUEMED LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 8/2016. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 18/12/2024 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־18 בדצמבר 2024 ב־12:30